{"name":"LIB Therapeutics LLC","slug":"lib-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPWGtCdC1PQWJ0ZjlrZ1M3LTY1VDNDT0JjeDZMRVprVG5tYWVndzdoeHBBekFnNW1vN29nc2J0YXFRSjljWUtLRlpPU0xySG0yUERTTEVFYkpVREl5dzk0MTd2anFhajhLbWd6UmVmWjRBLUVoNE5JR1l0TEVXVVRya1h6LXY5ZVpXUjhEb0praU1fSE1OQUplaw?oc=5","date":"2026-04-07","type":"pipeline","source":"openPR.com","summary":"PCSK9 Inhibitor Market Future Trends (2026-2033) | Monoclonal - openPR.com","headline":"PCSK9 Inhibitor Market Future Trends (2026-2033) | Monoclonal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQb3F0a1djbngzSUg5VHZuRGVnb0h5UDJkbkxDLUw4TG1LYkkwcUNJOFM2X1dxMXA0VHBxS2pGeFdQcS1ucklXdzc2UzEycTlBUU1WWHphVUxVYzdYMk5Lc2VTSE0zUHFTbUU0a1JjX2w0WGYzUzdJbkNDWFU3VnRMVkpRbFNmcGpsSkotX2pyU1podFpaZnZKNmZmNldvRnBYdXJQOUx3ZnhfLUFyQmhQdEJVQ1hGZWN6ckFKQ0hxSDZ5YTJjMDM0U2o3TzdTTExLREJoMDFfSWw2WXd4ZHY1eHREQ0ZsQjRObnRuYkln?oc=5","date":"2026-03-31","type":"pipeline","source":"Citeline News & Insights","summary":"Merck Does Not See Fasting Requirement Limiting Uptake For Enlicitide - Citeline News & Insights","headline":"Merck Does Not See Fasting Requirement Limiting Uptake For Enlicitide - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWm04emFZVFdWTUZEMEVaYmlpRFo5N24yc0dKeURtOEwxYlpNZmV0OEEwYmtjamJYTzd3WlFpR2RMTHpTUUx0U1Q0VFhJZGw0RkZoaDlFNGxoTXFEZFZMcHpjQXJvUWJ1NmUzLWFBT2VhbWRmMWxqRy1NcW9pY2h1LVhGblB1MHg2RjJ4R1JTWEFleUk0NGdpUC1hSmk?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Hypercholesterolemia Clinical Trial Pipeline Shows Potential - openPR.com","headline":"Hypercholesterolemia Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQN1ZuNTJydjZWUnlwekdCV2stb2NsaHZvdy1ud3FVNkZzQUYxQk16VjQwdXVna2E5ZW9PUUMxcGt4SHpSZHg5b2JmdWROZm00cTJ0UDItLV9vajY3Q0xZNm14eHpwZnA3TnpoVVZKcUxMelVWSng4dVNGc0tTLVoxekhHdw?oc=5","date":"2026-02-04","type":"pipeline","source":"Insightace Analytic","summary":"PCSK9 Inhibitors Market Size and Growth Analysis 2026 to 2035 - Insightace Analytic","headline":"PCSK9 Inhibitors Market Size and Growth Analysis 2026 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNbkFLS01TbU12NnQ5Zjh3RlYzNG5VS1d4YmZqM2NQTVlycmJqSjRQRURMQWNFSHNCbUVINDFfU1Vjb25rN2FYTXZicWtzcGVTVzJhNm05aVZYbXF5cWFPWWdYUzJmeHJQV1Fval9qQThfcEVqZVlLSkZUMzJLX0VRa1J3cm90a0dsMnZVUldiNGZJNjdmMXpOdlQ5b0x4SDk0cHpKN3FSX1J0TFhBQkI2aVl2U0FTV2VySDFCQWFJa3lEekFxLVB0ZUplZlFsYTN6NnE2bGUtblhpaS13U3dWY0pKMEdJRlozQXc?oc=5","date":"2025-12-16","type":"pipeline","source":"Citeline News & Insights","summary":"LIB Therapeutics Preparing To Launch New PCSK9 Inhibitor Option Lerochol - Citeline News & Insights","headline":"LIB Therapeutics Preparing To Launch New PCSK9 Inhibitor Option Lerochol - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPdHZhNnJwbXIxZVY0RUN4UGc5M2pSMmliNXBoVmlna3NjLTd5YTBneWFmWi1JZHZoNC1OZllFdW5qclpVYlhnVUI1bktxX2VDa3owYWluUkZYd0lBYk1yVVBFa0pXZXFFOGI3UDNrejhZQjRsYmJuVHZ2aFozdU05dVUtSU9BajRxT1BneGYwcWdjcHZiY3FUNnhxNDdDalJGVERJMTVHUEF5U01GUXc?oc=5","date":"2025-12-15","type":"regulatory","source":"Fierce Pharma","summary":"Cincinnati's LIB scores FDA approval for 3rd-generation PCSK9 drug Lerochol - Fierce Pharma","headline":"Cincinnati's LIB scores FDA approval for 3rd-generation PCSK9 drug Lerochol","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxNcHRHaGRhTjJTNGNsSkdzMHM4a1FVTEJSLTNFdXFVRnlHSl90S2czLWlMVHd4OHFaSXUzZ0VzNEplczdZUVk4VFo0X3A1X25uZzVEVEFISXZuc0RteEtJWnlSdGduUkFTQ2ZXb3doTjkyd0UxdmpOb2tyVXFyd1NTOW1rUzF5VGdudVNDX056NDIzN2h1SFFWNnlVMVBpR3c2RlMtcE5UMDNPSkxxYklueDVSVG9FTTJpNE5MclNhLUpuSWpaWm5rbjVYWWRUcXZTUk8wZzNVV05mTzg2Z0FwTHNyLXFWOUNXVjVYRkJpU2djUjhwMnZlMDVVaWVuQVJoV2g2elZsekxscGk5SHN1UnZGNHJjZXRvYlYwVWMtUFBOZ3BDMkZwRV9PX3JMbTZzWjNicXBSOWRWRzRDSjVpWFdrdk1yNEh3aUhxSk9TT0pobUliRXR0Y3VERQ?oc=5","date":"2025-09-11","type":"pipeline","source":"PR Newswire UK","summary":"Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight - PR Newswire UK","headline":"Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5IQmUzenFyWVNRbWlVVjRpS1VuSm5FcFRzdkJMQm4xVFM3ekU4Vmd6Y3RmTW5KbVNaYXBaM0ItRWdMN18wbU91eHJicXlCOWdhMHZDUUNSRU5hS1pRbVpKNVpCdmtyR2c3?oc=5","date":"2025-07-24","type":"trial","source":"Wiley Online Library","summary":"Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies - Wil","headline":"Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQWUV0WUhKYUJuek5Qa19selJLZ19CTGlRN0N1VWhnWU05WFBidi1PYWVrSEJiOUpxclE4enpZSDY4UktQaDZSZUdvX1B5UFdHVG4wSndVbl9UMU1vTU9ZLVJZU0NTZTFkSFJFZDU4ZkVTMlNoM0pqTkVHa2xLYjNScW13My11Yk5yRXktaTdsRThzQnR3bjZ4RUY4dlhOUnpEM2lYbXJwVWhaR0dLelNPTzhKMHIyUVlVWTRuTkhXeENrMWFWV25CTDQxcVZ0MmpfaHRJZDlpenlNelZMYjFWb2VJMTlVZ1JfTUh6MlJpX0tkaEZyYzJhN2tYdXU?oc=5","date":"2025-05-08","type":"pipeline","source":"prnewswire.com","summary":"LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - prnewswire.com","headline":"LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQcVJYZXgtRHdxZ04zNWVwWjdoLWVMVS00WHIzb21GM19jNHNUbldNakhEQjJlUlVCdmR1SjNka3RfVHhGd2N4Y1F0TUlFTjMwRG4yaVJsa3Q3cGFQYlRsNDkxeFVoTGM3blh2emdPcEstN2s0d2ZJTjM2bm1uaVpqdWt6eWNzZld6QVpEU1FZY1hwYUlISjF2YTJwOE44RmR2YWdKdEVXcFNQWFhiYnQ2dndTUFdaX0lGc21jaXUzRENQWUxsTHJiWVFLdTZWcWFSWHFyNlUzUFhKeUdDTUZaUlVNMEJDMGVpYXFyOERVdDNWSEpIdkpkUm5nU0NQclp1OUhKWGttLVhJakpUcHJ3?oc=5","date":"2025-05-06","type":"pipeline","source":"businesswire.com","summary":"LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6 - businesswire.com","headline":"LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow Ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNQmljSDdPTDRPcDZxQkV3TUt6TXRfSjZ2Y29FNHdQNXd1X2hTWE8tbE5KZ3ZiUlAwcGptNnVDdEJiT0VReEdFSklKVjRJcXhIN1BUcXdVU0M2UFBwSGJIdVVVelI3Rm1ic2xGYTlKZzZueGFIRTBVdkZnNGhObFNJSkdYQjZsa19yZDlRUEJOcE5oa3FVZ21tY05HTXdzQkNyMDhNYmMxa194V1FzSUV1T1J2N1BtajMtVXVZRFk0b1FKcFoyZ3A0RUFhQVhuOGRSM1pEdWZaTGg3emo1U3VqOE05cmhmek5Ua2pqcUlDbVV2amxFVW04VzRNNmdPT3BUY1ZDMUVkMDg?oc=5","date":"2024-12-16","type":"regulatory","source":"BioSpace","summary":"LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol - BioSpace","headline":"LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5pZWRXYUlGWFpob0hUM0hhWHpJOGVMeFczMXlEalZsdktGYzdwckx1UDdWSWdkaGdyVTVLdjlhZWNLUWtFQUlSRDB6WXpYTGlWTGpJOGVDNjJhRzdlXzd5NmFPM0pjNElPZVZlM1lCdm1XRjh0VWc?oc=5","date":"2023-09-13","type":"deal","source":"Pharmaceutical Technology","summary":"Hasten and LIB Therapeutics enter $325m CVD drug development deal - Pharmaceutical Technology","headline":"Hasten and LIB Therapeutics enter $325m CVD drug development deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}